Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28594559 | 0.85 | GRM5 (0.44) | GRM5 | |
| SCHEMBL26645516 | 0.82 | NR1H2 (0.46) | NR1H2GRM5MAPK1ACHEKIT | |
| SCHEMBL23778204 | 0.79 | PIK3R1 (0.41) | NR1H2 | |
| SCHEMBL12307580 | 0.77 | MEN1 (0.45) | NR1H2ACHE | |
| SCHEMBL12307411 | 0.76 | NR1H2 (0.45) | TSHRNR1H2GRM5MAPK1 | |
| SCHEMBL23779080 | 0.75 | HDAC6 (0.49) | GRM5 | |
| SCHEMBL23778200 | 0.75 | NR1H2 (0.39) | NR1H2 | |
| SCHEMBL12307412 | 0.74 | NR1H2 (0.48) | ATMNR1H2GRM5MAPK1 | |
| SCHEMBL26645720 | 0.74 | NR1H2 (0.44) | NR1H2GRM5 | |
| SCHEMBL12335631 | 0.73 | NR1H2 (0.46) | ATMNR1H2GRM5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009931-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-01-13 | — | — | US | disclosed |
| EP-3873907-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009931-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, CDKN1A | ATM 3945/4885TSHR 4190/4885ALOX15 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.